. Author manuscript; available in PMC: 2014 Aug 1.

Published in final edited form as: J Consult Clin Psychol. 2013 Jan 21;81(4):627–638. doi: 10.1037/a0031530

Table 3a.

Mixed Model Parameter Estimates for the Prediction of HAM-D Symptom Reduction Across Treatment Among Patients Receiving CBASP + ADM (n = 111)

	Estimate	SE	t	Significance	95% CI Lower	95% CI Upper	d
Intercept¹	14.43	.45	34.16	p < .001	14.93	16.71	4.59
Female Gender	−.06	.62	.11	p = .91	−1.29	1.14	.01
Age	.01	.03	.45	p = .66	−.04	.07	.06
Baseline GAF	−.25	.04	−6.80	p <.001	−.32	−.17	.91
Early alliance	−.22	.03	−7.48	P < .001	−.28	−.16	1.00
Early symptom change	.14	.05	3.01	p = .003	.05	.22	.40

Note:

Intercept reflects estimated mean HAM-D score across all time points.

Gender reference group = male. GAF = Global Assessment of Functioning.